Fairfield University is a private, co-educational undergraduate and master's level teaching-oriented university located in Fairfield, Connecticut, in the New England region of the United States. It was founded by the Society of Jesus in 1942, and today is one of 28 member institutions of the Association of Jesuit Colleges and Universities. The primary objectives of a Fairfield University education are to develop the creative intellectual potential of its students and to foster in them ethical and religious values and a sense of social responsibility. All schools of the university are committed to a liberal humanistic approach to education, which encourages interdisciplinary learning.About 3,500 undergraduate and 1,200 graduate students study in Fairfield's five schools and colleges: The Fairfield University College of Arts and science, The Charles F. Dolan School of Business, The School of Engineering, The School of Nursing, and The Graduate School of Education and Allied Professions. The university is notable academically for its nationally recognized accounting and nursing programs along with its liberal arts and science programs which have produced a MacArthur Fellow, a Guggenheim Fellow and sixty-two Fulbright Scholars since 1993. In addition, two Fairfield faculty members were named consecutive Connecticut Professors of the Year by the Carnegie Foundation for the Advancement of Teaching in 2009 and 2010 in recognition of their extraordinary dedication to undergraduate teaching. Wikipedia.
News Article | April 17, 2017
LearnHowToBecome.org, a leading resource provider for higher education and career information, has released its list of Connecticut’s best colleges and universities for 2017. Of the 19 four-year schools that made the list, Yale University, Fairfield University, Quinnipiac University, University of Hartford and University of Connecticut scored highest. Of the 12 two-year schools that were also included, Capital Community College, Manchester Community College, Naugatuck Valley Community College, Three Rivers Community College and Gateway Community College were the top five schools. A full list of the 31 schools is included below. “As Connecticut’s job market fluctuates, many people consider earning a certificate or degree to help change or bolster their career,” said Wes Ricketts, senior vice president of LearnHowToBecome.org. “These Connecticut schools have proven themselves with solid educational programs, but have also taken extra steps to provide resources that translate into career success for students.” To be included on Connecticut’s “Best Colleges” list, schools must be regionally accredited, not-for-profit institutions. Each college is also scored on additional metrics such as employment resources, academic counseling, financial aid availability, annual alumni earnings 10 years after entering college, student/teacher ratios and graduation rates. Complete details on each college, their individual scores and the data and methodology used to determine the LearnHowToBecome.org “Best Colleges in Connecticut” list, visit: The Best Four-Year Colleges in Connecticut for 2017 include: Albertus Magnus College Central Connecticut State University Connecticut College Eastern Connecticut State University Fairfield University Goodwin College Mitchell College Quinnipiac University Sacred Heart University Southern Connecticut State University Trinity College University of Bridgeport University of Connecticut University of Hartford University of New Haven University of Saint Joseph Wesleyan University Western Connecticut State University Yale University The Best Two-Year Colleges in Connecticut for 2017 include: Asnuntuck Community College Capital Community College Gateway Community College Housatonic Community College Manchester Community College Middlesex Community College Naugatuck Valley Community College Northwestern Connecticut Community College Norwalk Community College Quinebaug Valley Community College Three Rivers Community College Tunxis Community College ### About Us: LearnHowtoBecome.org was founded in 2013 to provide data and expert driven information about employment opportunities and the education needed to land the perfect career. Our materials cover a wide range of professions, industries and degree programs, and are designed for people who want to choose, change or advance their careers. We also provide helpful resources and guides that address social issues, financial aid and other special interest in higher education. Information from LearnHowtoBecome.org has proudly been featured by more than 700 educational institutions.
News Article | April 24, 2017
Emagination Computer Camps, a national operator of summer technology camps for children since 1982, offers summer programs which blend fun technology learning with the life-long benefits of a traditional summer camp. “Over the past several years, there has been an incredible rise in the interest in summer STEM learning opportunities,” said Craig Whiting, president of Emagination. “At Emagination, we’ve always believed in balancing educational time in front of a computer and the developmental benefits which come from non-technology, interpersonal activities.” There are many aspects to Emagination’s program which differentiates it from other technology camps. Over a two-week camp session, each camper takes four workshops; three are technology workshops, which they choose from a selection of 26 that Emagination offers, and one is a recreation workshop. Campers are organized into camper groups, similar to a traditional camp’s cabin groups, to foster socialization and building friendships through small group activities. Structured and unstructured playtime is incorporated throughout the campers’ day with the camp’s “Refresh Time,” an hour after lunch to hang out with friends, play games, or socialize before afternoon workshops, and “Evening Program,” where campers choose from a selection of activities driven by camper interests. The Saturday in the middle of the session is filled with fun outdoor games and activities such as a slip ‘n slide, color run, Human Pac-Man, and many more. A BBQ, movie night, and Local Area Network (LAN) gaming tournament are all part of the camp’s “Super Saturday.” Returning high school-aged campers can participate in the camp’s Teen Leadership Program, which gives them the opportunity to learn leadership and life-skills and to put those skills into action by assisting staff both in the classroom and in outdoor activities. “Our mission is to ‘educate, entertain, and help develop healthy kids,’” said Whiting, “and we believe we deliver on that mission with our programs.” Emagination Computer Camps is offered at Boston College in Newton, Massachusetts, Fairfield University in Fairfield, Connecticut, Rosemont College in Rosemont/Bryn Mawr, Pennsylvania, Mercer University in Atlanta, Georgia, and Lake Forest College in Lake Forest, Illinois. Emagination also offers two specialty STEM programs for teenagers, Emagination Programming Camp and Emagination Game Design Camp. In Emagination Programming Camp, teens ages 13 – 17 learn how to program with C# - the world’s most popular programming language for creating Windows applications. This two-week day or overnight STEM program is balanced with daily recreation and a full evening program for overnight campers. In Emagination Game Design Camp, teens 15 - 18 experience what it's like to work in the video game development industry. They join a team to build a playable 3D game, tour a game design studio, and learn from guest speakers. This two-week overnight only STEM program is an immersive experience, but balanced with plenty of time for daily outdoor activities and recreation. For more information about Emagination Computer Camps, Emagination Game Design, and Emagination Programming Camp visit http://www.computercamps.com.
News Article | May 9, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today the appointment of several experienced industry leaders to key leadership roles including: Manmeet S. Soni, Chief Financial Officer; Theresa Heggie, Senior Vice President, Head of Europe and Canada; Peter Smith, Ph.D., Senior Vice President, Early Development; and Alan Eisenberg, Vice President, Global Public Policy and Government Relations. "We are thrilled to welcome Manmeet, Theresa, Peter, and Alan to Alnylam at an exciting moment in our history. Each of these individuals brings a critical set of skills to the organization as we transition from a late-stage research and development company to a multi-product, commercial-stage company with a robust and sustainable pipeline of innovative medicines,” said John Maraganore, Ph.D. Chief Executive Officer of Alnylam. "This expansion of our leadership team solidifies and strengthens our path forward." “I couldn’t imagine a more exciting time to join Alnylam,” said Mr. Soni. “It’s an honor to have the opportunity to work with such a talented group of individuals focused on bringing forward a new class of medicines for the betterment of lives of patients in need. I look forward to using my experience in building and leading commercial finance teams and capabilities to help Alnylam execute on its strategy, goals and transition towards an independent commercial-stage company.” In this role Mr. Soni will provide strategic leadership in the overall financial management of Alnylam, including for the global finance, investor relations and communications teams. Manmeet is the former Chief Financial Officer and Treasurer of ARIAD Pharmaceuticals, Inc., where he played a central role in the strategic review, turnaround and subsequent acquisition of ARIAD Pharmaceuticals, Inc. by Takeda Pharmaceuticals Company Limited. Before joining ARIAD Pharmaceuticals, Inc., Manmeet worked at Pharmacyclics, Inc., where he served most recently as Chief Financial Officer and Treasurer. Mr. Soni also played a vital role in the acquisition of Pharmacyclics, Inc. by Abbvie, Inc. for $21 billion. Previously, Mr. Soni worked at ZELTIQ Aesthetics Inc., and PricewaterhouseCoopers San Jose, in the Life Science and Venture Capital Group. Prior to that, he worked at PricewaterhouseCoopers, India. Mr. Soni is currently a board member and audit committee chair at Genoscience Pharma. He graduated from Hansraj College at Delhi University in India. He is a Certified Public Accountant, licensed in the state of California and a Chartered Accountant from India. "Expanding Alnylam’s operations into Europe and Canada is being done in recognition of the broad commercial rights we have in these regions and the important role they will play in our global commercial strategy," commented Ms. Heggie. "Drawing on my expertise from numerous European and global leadership roles, I look forward to advancing this important phase of the Company’s commercial evolution and bringing new treatments to patients in Europe and Canada." In this role Ms. Heggie will be responsible for the strategic direction and activity of all of Alnylam’s operations in Europe and Canada including building the go-to-market strategy across multiple products and therapeutic areas. Most recently she served as the Chief Marketing and Strategy Officer at The British United Provident Association (Bupa). Previously, Ms. Heggie held various senior commercial positions at Shire Human Genetic Therapies (and formerly TKT) including the roles of Vice President and General Manager of EMEA, Chief Executive Officer of Jerini AG (a Shire acquisition), and Senior Vice President of Global Commercial Operations. Earlier, at Baxter Healthcare she held numerous roles including Vice President of Global Marketing. Early in her career, Ms. Heggie held a variety of sales and marketing positions at Janssen Pharmaceuticals. She formerly served as a member of the board of directors of Swedish Orphan Biovitrum AB. Theresa received a BSc from Cornell University. Ms. Heggie will report to Barry Greene, President and will be based at Alnylam’s European headquarters in Zug, Switzerland. “Having the ability to work at an organization with a product engine as productive as Alnylam’s is a very special opportunity,” added Dr. Smith. “The ability to grow and develop the Early Development team across the pipeline of RNAi therapeutics at Alnylam will be paramount as we advance the translation of promising science toward new medicines for patients.” In this role, Dr. Smith will be responsible for all aspects of non-clinical safety, drug metabolism and pharmacokinetics, bioanalysis and biomarker programs, providing both scientific and drug development leadership. Dr. Smith brings more than 30 years of pharma industry experience to Alnylam, most recently joining from Moderna, where he was Head of R&D Non-Clinical. He joined Moderna from Millennium Pharmaceuticals, where he most recently served as co-head of R&D and a member of the company’s management team. In this role, he was responsible for management of all Non-Clinical groups and Pharmaceutical Sciences. His extensive experience in drug discovery and development spans multiple therapeutic areas and therapeutic modalities. Over the course of Dr. Smith’s career, he has had oversight of the non-clinical development of multiple, currently marketed therapeutics including CELEBREX®, INSPRA®, VELCADE® and ENTYVIO®, and also deep involvement in the development of numerous other products. Dr. Smith has a B.S. in biology from Fairfield University and a Ph.D. in Pharmacology and Toxicology from the University of Arizona. His postdoctoral fellowship in biochemical toxicology was undertaken at SmithKline. He has published and presented extensively in the pharm/tox area as well as in the area of drug development. Dr. Smith will report to Akshay Vaishnaw, Executive Vice President of Research and Development. “In an era of intense scrutiny around value and access to innovation, I look forward to drawing on my political and policy experience both in the private and public sectors to help Alnylam achieve its objectives,” said Mr. Eisenberg. “I’m deeply aligned with the mission and vision of Alnylam and look forward to working on behalf of the company with our governmental stakeholders globally.” In this role, Alan will lead federal, state and local government affairs and public policy initiatives globally. Alan joins Alnylam from Celgene where he was the Vice President for Federal Government Relations. In this role, he led Celgene’s Federal Government Relations function and had direct responsibility for the Company’s public policy engagement with Congress, relevant Executive Branch agencies and other Washington, D.C. based stakeholders. Prior to Celgene, Mr. Eisenberg was Executive Vice President for Emerging Companies & Business Development at the Biotechnology Innovation Organization (BIO), leading BIO’s services and advocacy efforts for BIO’s pre-market and early stage commercial companies, in addition to serving in other senior leadership roles at BIO. Previously, Mr. Eisenberg served as Health and Economics Policy Advisor to Congressman Jim Greenwood and prior to that, he served on the staff of the Senate HELP Public Health Subcommittee, and also was a legislative assistant for Congressman John Shadegg. Earlier in his career he spent four years with Ford Motor Company. Mr. Eisenberg holds a Master in Public Policy degree from Harvard University, a Master of Science in Finance degree from George Washington University, and a Bachelor of Science degree from Union College. Mr. Eisenberg will report to Laurie Keating, Senior Vice President and General Counsel. Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of patients who have limited or inadequate treatment options. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically-validated approach for the treatment of a wide range of debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust discovery platform and deep pipeline of investigational medicines, including three product candidates that are in late-stage development or will be in 2017. Looking forward, Alnylam will continue to execute on its “Alnylam 2020” strategy of building a multi-product, commercial-stage biopharmaceutical company with a sustainable pipeline of RNAi-based medicines. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on Twitter at @Alnylam. Various statements in this release concerning Alnylam's future expectations, plans and prospects, including, without limitation, Alnylam's views with respect to the potential for RNAi therapeutics, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results and future plans may differ materially from those indicated by these forward-looking statements as a result of various important risks, uncertainties and other factors, including, without limitation, Alnylam's ability to discover and develop novel drug candidates and delivery approaches, successfully demonstrate the efficacy and safety of its product candidates, the pre-clinical and clinical results for its product candidates, which may not be replicated or continue to occur in other subjects or in additional studies or otherwise support further development of product candidates for a specified indication or at all, actions or advice of regulatory agencies, including actions by regulators concerning product candidates, which may affect the initiation, timing and progress of clinical trials, obtaining, maintaining and protecting intellectual property, Alnylam's ability to enforce its intellectual property rights against third parties and defend its patent portfolio against challenges from third parties, obtaining and maintaining regulatory approval, pricing and reimbursement for products, progress in establishing a commercial and ex-United States infrastructure, competition from others using technology similar to Alnylam's and others developing products for similar uses, Alnylam's ability to manage its growth and operating expenses, obtain additional funding to support its business activities, and establish and maintain strategic business alliances and new business initiatives, Alnylam's dependence on third parties for development, manufacture and distribution of products, the outcome of litigation, the risk of government investigations, and unexpected expenditures, as well as those risks more fully discussed in the "Risk Factors" filed with Alnylam's most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) and in other filings that Alnylam makes with the SEC. In addition, any forward-looking statements represent Alnylam's views only as of today and should not be relied upon as representing its views as of any subsequent date. Alnylam explicitly disclaims any obligation, except to the extent required by law, to update any forward-looking statements.
News Article | May 11, 2017
HealthSmart, the largest independent benefits administrator in the country, is pleased to announce the appointment of Tom Mafale as Chief Sales Officer, reporting to Bill Wallace, HealthSmart’s Executive Vice President. Mafale comes to HealthSmart from Emblem Health, where he served as Corporate Vice President and Sales Officer. Prior to Emblem Health, he served as Executive Vice President and Chief Sales Officer at M3 Healthcare Technologies, and Senior Vice President/Head of Sales Operations, National Accounts for Aetna. Mafale also served in several sales leadership positions during his 20 years at United Healthcare, including the Senior Vice President and Chief Operating Officer of their Public-Sector business. “We are very excited to have Tom joining our senior leadership team,” said Bill Wallace, “his exceptional experience and expertise in both consultative selling and sales organization management make him the ideal person to help us take HealthSmart to its next level of success.” “I’m excited to join such a dynamic organization and to lead the HealthSmart sales team,” said Mafale. “This company is poised to become the gold-standard of the industry, delivering unique services that improve member outcomes and provide strong employer benefit savings.” Mafale is a graduate of Fairfield University, with a B.S. in Business Management. His community involvement includes serving on the Board of United Way.
Xu M.,Fairfield University
Optics Express | Year: 2011
The scattering-phase theorem states that the values of scattering and reduced scattering coefficients of the bulk random media are proportional to the variance of the phase and the variance of the phase gradient, respectively, of the phase map of light passing through one thin slice of the medium. We report a new derivation of the scattering phase theorem and provide the correct form of the relation between the variance of phase gradient and the reduced scattering coefficient. We show the scattering-phase theorem is the consequence of anomalous diffraction by a thin slice of forward-peaked scattering media. A new set of scattering-phase relations with relaxed requirement on the thickness of the slice are provided. The condition for the scattering-phase theorem to be valid is discussed and illustrated with simulated data. The scattering-phase theorem is then applied to determine the scattering coefficient μs, the reduced scattering coefficient μs', and the anisotropy factor g for polystyrene sphere and Intralipid-20% suspensions with excellent accuracy from quantitative phase imaging of respective thin slices. The spatially-resolved μs, μs' and g maps obtained via such a scattering-phase relationship may find general applications in the characterization of the optical property of homogeneous and heterogeneous random media. © 2011 Optical Society of America.
Henkel L.A.,Fairfield University
Psychological Science | Year: 2014
Two studies examined whether photographing objects impacts what is remembered about them. Participants were led on a guided tour of an art museum and were directed to observe some objects and to photograph others. Results showed a photo-taking-impairment effect: If participants took a photo of each object as a whole, they remembered fewer objects and remembered fewer details about the objects and the objects' locations in the museum than if they instead only observed the objects and did not photograph them. However, when participants zoomed in to photograph a specific part of the object, their subsequent recognition and detail memory was not impaired, and, in fact, memory for features that were not zoomed in on was just as strong as memory for features that were zoomed in on. This finding highlights key differences between people's memory and the camera's "memory" and suggests that the additional attentional and cognitive processes engaged by this focused activity can eliminate the photo-taking-impairment effect. © The Author(s) 2013.
Agency: NSF | Branch: Standard Grant | Program: | Phase: WORKFORCE IN THE MATHEMAT SCI | Award Amount: 260.00K | Year: 2014
The Fairfield University Research Experiences for Undergraduates Program in Mathematics and Computational Science is an eight-week summer program designed to engage talented undergraduates in original mathematics and computing research, beyond the college curriculum. The program hosts nine students per summer, providing on-campus housing and student stipends. The participants spend their time working and learning in small groups, with each group in close consultation with an individual Fairfield University faculty mentor on research topics drawn from the mentors field of expertise.
The principal goal of the program is to prepare the participants for research-based scientific careers, and to engender in each student a deep understanding not only of the importance of individual scientific research, but also of the broader context of collaboration into which that research fits. This is achieved by providing the students with the experience of a research cohort. This collaborative research environment - students working with faculty and with each other - also allows for the general advancement of the mathematics and computing disciplines, and fosters the continuing scholarly and pedagogical development of all the academic professionals involved.
Agency: NSF | Branch: Standard Grant | Program: | Phase: | Award Amount: 168.50K | Year: 2014
The research funded by this grant will focus in large part on the study of mathematical models of particle systems with collision interactions that are central to the field of statistical mechanics, and in particular to our understanding of chaotic dynamical systems. Such systems play an important role in the study of non-equilibrium dynamics, which model, for example, the motion of particles subjected to external forces or nonelastic collisions. Other examples of non-equilbrium dynamics include systems in which mass or energy is allowed to escape, and large-scale systems of smaller interacting components which exchange mass or energy. Such systems have been used in theoretical physics and chemical engineering to model atom traps, explore mechanisms for heat conduction in solids and investigate metastability in molecular processes. Rigorous mathematical results obtained during the course of this grant will aid in the interpretation of these studies as well as suggest new directions of inquiry. This grant also supports the involvement of undergraduates in mathematics research. Using the highly visual nature and physical motivation of the problems outlined above, the author will recruit undergraduate students to work on these topics during each summer funded by the grant. Special emphasis will be given to recruiting students from underrepresented groups in research mathematics. Students will disseminate results of their research at poster sessions and through publication in undergraduate or research journals, as appropriate. By stimulating interest in research careers in mathematics and creating a peer community supportive of that interest, the grant will contribute to the important goal of integrating research and education.
Much research in dynamical systems focuses on closed systems in which the dynamics are self-contained. In many modeling situations, however, such a global view is not possible and it becomes necessary to study local systems that are influenced by other unknown systems, possibly on different scales. Such considerations motivate many of the systems to be studied during the course of this grant: systems in which mass or energy may enter or exit through deterministic or random mechanisms. The grant is organized around three specific projects: The first project investigates the statistical properties of both classical and non-equilibrium particle systems, which constitute an important class of models from statistical mechanics as described above; the second concerns open systems, which are inspired by physical models in which mass or energy is allowed to escape; the third project investigates the behavior of dynamical systems which are comprised of (possibly infinitely many) smaller components linked together, with orbits or energy allowed to pass between them. When focused on one component at a time, such systems generalize the discussion of open systems in a natural way by allowing both entry and escape. The intellectual merit of the research activity funded by the grant stems from the depth of the analytical tools to be developed as well as the complexity and variety of the systems under consideration. Using his recent work concerning the spectral decomposition of the transfer operator for dispersing particle systems, the author will investigate both equilibrium and non-equilibrium models from statistical mechanics. This approach is expected to resolve a longstanding conjecture by Bowen and Ruelle regarding the continuous time flow and to provide rigorous analysis of physically important quantities such as entropy production. A second tool the author will use is the construction of Markov extensions (a generalization of finite and countable Markov partitions), which make no Markovian assumptions on the dynamics and are widely applicable to nonuniformly hyperbolic systems, including Hénon maps and a wide variety of particle systems. The application of such tools to systems out of equilibrium, open coupled map lattices and extended systems will represent significant advances in the study of such systems. Efforts to understand these tools in one context strengthens them and aids in their application to other areas of mathematics. Their intellectual interest is enhanced by the application of these ideas to resolve problems posed and approached formally in the physics literature.
Agency: NSF | Branch: Standard Grant | Program: | Phase: MAJOR RESEARCH INSTRUMENTATION | Award Amount: 271.41K | Year: 2016
With this award from the Major Research Instrumentation Program (MRI) and support from the Chemistry Research Instrumentation Program (CRIF), Professor Jillian Smith-Carpenter from Fairfield University and colleagues Matthew Kubasik, John Miecznikowski, Aaron Van Dyke and Catherine Andersen have acquired a matrix assisted laser desorption/ionization time-of-flight mass spectrometer (MALDI-TOF mass spectrometer). In general, mass spectrometry (MS) is one of the key analytical methods used to identify and characterize small quantities of chemical species embedded in complex matrices. A laser impinging on the inert matrix embedded with the sample, vaporizes and ionizes the sample. The ions pass into the mass spectrometer where the masses of the parent ion and its fragment ions are measured. In a time-of-flight instrument the ions are accelerated by an electric field to allow further characterization. MALDI TOF combines gentle ionization (ideal for producing intact ions of peptides, proteins, nucleic acids, carbohydrates, synthetic polymers, and other similarly sized species) with a detection mode that offers an excellent balance between sensitivity and accuracy across a wide mass range. The collision-induced dissociation facilitates fragmentation of molecular ions in the gas phase. This highly sensitive technique allows identification and determination of the structure of molecules in a complex mixture. The acquisition strengthens the research infrastructure at the University and regional area. The instrument broadens participation by involving diverse students in research and research training with this modern analytical technique and is shared with students at the University of Bridgeport and numerous laboratories in Southwestern Connecticut.
The award is aimed at enhancing research and education at all levels, especially in areas such as (a) obtaining the polymeric distribution of disulfide cross-linked peptide oligomers and aggregates; (b) exploring small molecule strategies for protein labeling; (c) understanding the role of high-density lipoproteins in the regulation of immune activity; (d) developing solid-phase peptide synthesis of alpha,alpha-dialkylated amino acids and (e) developing aqueous transition metal catalysts.
Agency: NSF | Branch: Continuing grant | Program: | Phase: Physiolg Mechansms&Biomechancs | Award Amount: 404.31K | Year: 2014
Locomotion and feeding are essential behaviors for the survival and reproductive fitness of most animals. However, little is understood about why some individuals within a population outperform others and are better suited to their habitat. Populations of bluegill sunfish often diverge into two different body forms based on their habitat: a deeper-bodied shallow water form or a streamlined deep water form. This variation creates an ideal system for investigating the relationships between form, function and adaptation to habitat.
This project will integrate studies of behavior in the field, external and internal morphology and muscle physiology, energy metabolism, swimming performance, feeding mechanics and fitness measurements in order to quantify variation in swimming and feeding performance within a single population of bluegill from pelagic and littoral habitats. Results from this research will provide unprecedented insight into the complex interrelationships of body form, swimming and feeding performance and fitness in fish. Moreover, this research will provide an experimental and analytical framework that could be applied to any animal system. This proposal is a collaborative effort among three liberal arts institutions, therefore an important component of the project will be the mentoring of a postdoctoral researcher and the training of undergraduates, a high proportion of whom will continue their education in graduate or professional schools, increasing the participation of underrepresented groups in the sciences. The research will be implemented in an outreach program aimed to introduce basic concepts of biomechanics and physiology to underrepresented K-12 students at neighboring schools.